Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.

Cabibbo, G., Rolle, E., De Giorgio, M., Genco, C., Pressiani, T., Spada, F., et al. (2011). Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. EXPERT REVIEW OF ANTICANCER THERAPY, 11(12), 1807-1816 [10.1586/era.11.139].

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

Fagiuoli S
2011

Abstract

Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.
Articolo in rivista - Articolo scientifico
cirrhosis; hepatocellular carcinoma; liver cancer; management; sorafenib; systemic therapy; treatment;
English
1807
1816
10
Cabibbo, G., Rolle, E., De Giorgio, M., Genco, C., Pressiani, T., Spada, F., et al. (2011). Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. EXPERT REVIEW OF ANTICANCER THERAPY, 11(12), 1807-1816 [10.1586/era.11.139].
Cabibbo, G; Rolle, E; De Giorgio, M; Genco, C; Pressiani, T; Spada, F; Sacco, R; Fagiuoli, S
File in questo prodotto:
File Dimensione Formato  
CABIBBO EXP REW ANTIC THER 2011.pdf

Solo gestori archivio

Dimensione 634.31 kB
Formato Adobe PDF
634.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/354284
Citazioni
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 22
Social impact